Sánchez-Carrillo C, Cotarelo M, Cercenado E, Vicente T, Blázquez R, Bouza E
Servicio de Microbiología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
J Antimicrob Chemother. 1996 Jan;37(1):151-4. doi: 10.1093/jac/37.1.151.
The in-vitro activity of sparfloxacin and eight other antimicrobial agents against 64 non-tuberculous mycobacteria (non-MAI) (40 rapidly growing and 24 slowly growing) was compared with those of ciprofloxacin, ofloxacin, amikacin, tobramycin, cefoxitin, imipenem, clarithromycin and doxycycline. Sparfloxacin presented the same activity as ciprofloxacin, being highly active against rapidly growing mycobacteria and showing good in-vitro activity against slowly growing mycobacteria. Amikacin was very active against rapidly growing mycobacteria and clarithromycin presented good activity against all mycobacteria tested. These results suggest that sparfloxacin is a valid agent to be considered in the treatment of Mycobacterium spp. infections.
将司帕沙星及其他8种抗菌药物对64株非结核分枝杆菌（非鸟分枝杆菌）（40株快速生长菌和24株缓慢生长菌）的体外活性与环丙沙星、氧氟沙星、阿米卡星、妥布霉素、头孢西丁、亚胺培南、克拉霉素和强力霉素进行了比较。司帕沙星表现出与环丙沙星相同的活性，对快速生长的分枝杆菌具有高活性，对缓慢生长的分枝杆菌也显示出良好的体外活性。阿米卡星对快速生长的分枝杆菌非常活跃，克拉霉素对所有测试的分枝杆菌都具有良好活性。这些结果表明，司帕沙星是治疗分枝杆菌属感染时可考虑使用的有效药物。
